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ABSTRACT 
Depression is a complex disorder with an average lifetime prevalence from 11.1% to 
14.6%. It causes serious disability and is a significant public health problem worldwide. 
The etiology of depression is heterogeneous and multifactorial. Traditionally, researchers 
have tried to investigate depression from biochemical, genetic, environmental and 
behavioral perspectives. Since few biomarkers are available, diagnosis and treatment are 
still based on clinical assessment and are far from satisfactory. In recent years, depression 
has been proposed to be a state of “accelerated biological aging”, with an increased risk of 
comorbidity with other ageing-related conditions such as diabetes, cardiovascular disease 
and dementia. There is accumulating evidence to support that depression itself is in fact a 
state that involves telomere dysfunction, a prominent feature in the ageing process. 
Epigenetic regulation, with an emerging role in a number of complex disorders, constitutes 
a fusion between the results of genetic, biochemical and environmental factors. The aim of 
this thesis was to investigate the pathophysiology of depression with a focus on 
mechanisms that are perturbed in telomere biology and epigenetic regulation. Specifically, 
in paper I and III: telomere length and the genetic variation in the hTERT gene were 
examined in relation to lithium treatment, to depression disorder and depressive episodes in 
bipolar disorder in human cohorts. In paper II, we used a genetic rat model of depression 
(FSL) to study hippocampal telomere length and telomerase activity, and investigated the 
mechanism of how lithium affects telomere length. The epigenetic mechanisms potentially 
involved in depression, specifically DNA methylation/hydroxymethylation and miRNAs 
were investigated in the prefrontal cortex region of the FSL rats in paper IV and V, 
respectively. The major finding from the thesis work includes 1) telomere lengths were 
decreased in saliva DNA from patients with adult depression 2) genetic variation in hTERT 
may influence the susceptibility to depression 3) telomeres and telomerase activity are 
dysfunctional in the hippocampus of the depressed FSL rats 4) long-term lithium treatment 
is associated with longer telomeres in bipolar disorder especially when therapeutically 
efficacious 5) lithium treatment may normalize hippocampal telomerase dysfunction 
through activation of β-catenin in the rat 6) sodium butyrate exerts antidepressant-like 
effect and the suggestive epigenetic effects may include DNA methylation changes that are 
mediated by the demethylation-facilitating enzyme TET1 in the rat 7) elevation of cytokine 
Il6 in the prefrontal cortex is associated with depression-like states and may involve 
disturbance in let-7 biogenesis in the rat 8) physical exercise appears to normalize Il6 and 
let-7 levels through regulatory processes upstream of primary miRNA transcription in the 
rat. 
 
Keywords: telomere length, hTERT, telomerase activity, depression, FSL, lithium, TET, 
sodium butyrate, methylation, hydroxymethylation, miRNA, let-7 
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1 INTRODUCTION 
Depression was initially called "melancholia" which first appeared in ancient Mesopotamian 
texts written around 2000 B.C. It was documented as one of four humors in the old medical 
beliefs. From ancient Greeks and Romans, for thousands of years, depression has been 
debated back and forth as to whether it was best thought as a mental or physical disease. 
Nowadays we define depression, or a more clinical term “major depressive disorder”, as a 
mental disorder characterized by pervasive and persistent low mood that is accompanied by 
low self-esteem and a loss of interest or pleasure in normally enjoyable activities [1]. 
However, it became the accepted view for scientists that depression can actually have many 
causes, and different approaches for treatment are considered to be important in helping 
depression patients “out of the blue”. Depression is a commonly occurring and recurrent 
disorder. Specifically, the estimated lifetime prevalence is from 11.1% to 14.6% between 
different countries [2] and approximately 60% of people who had a first lifetime episode 
would develop a second one [3]. It is noteworthy that depression is highly comorbid with 
other medical diseases that associates with accelerated biological aging (e.g. cardiovascular 
disease and type 2 diabetes) [4-6] and recently mounting evidence seem to support the 
accelerated biological-aging conception in depression [7; 8]. The importance of studying 
depression is also reflected by the global projections of disease burden by World Health 
Organization (WHO) which ranked depression as the second leading cause of burden of 
disease in 2030 worldwide [9]. Therefore, from both individual and public health 
perspectives, depression is a problem of major significance and importance. 
In the introduction section of the thesis, some major definitions and background information 
are introduced with the purpose to help everyone, also readers who are not working in the 
psychiatric field, to understand the topics studied in the constituent papers. I hope this thesis 
work can raise the awareness of people who have ignored or underestimated the significance 
of studying mental disorder.    
 
 
 
 
 
        “Success is not final, failure is not fatal: it is the courage to continue that counts.” 
                                                                                                              ― Winston Churchill  
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1.1 DEPRESSION 
In this section, an overview of depression is provided which includes the symptoms and 
diagnoses criteria, the current view of etiology and relevant treatments for depression. A 
brief introduction of bipolar disorder is also included which contains the diagnoses and 
treatment options.  
1.1.1 Symptoms and clinical diagnoses 
Depressive disorders include a spectrum of disorders with the common features being the 
presence of sadness or irritable mood accompanied by somatic and cognitive changes that 
significantly affect the individual’s capacity of functioning (DSM-V). Depression is a highly 
recurrent and dimensional illness with the affected persons moving in and out of diagnostic 
subtypes, such as Major Depression, Dysthymia and Minor Depression [10]. The symptoms 
and diagnostic criteria are determined on the basis of clinical interviews, by using diagnostic 
classification systems, including Diagnostic and Statistical Manual of Mental Disorders 
(DSM) and International Statistical Classification of Diseases and Related Health Problems 
(ICD), with no biochemical or physiological test available. According to DSM-IV (and also 
DSM-V), the main criteria include depressed mood or a loss of interest or pleasure in daily 
activities (anhedonia) consistently for at least a two week period. Other symptoms include 
significant change in weight and appetite, change in sleep (insomnia or hypersomnia), 
change in activity (psychomotor agitation or retardation), fatigue or loss of energy, 
guilt/worthlessness, diminished ability to think or concentrate and suicidal thoughts. General 
practitioners were able to make routine diagnoses of depression only in about 50% of the 
cases [11].  
Depressive episodes are common in bipolar disorder (BD). Bipolar disorder originally called 
manic-depressive illness, is a mental disorder characterized by recurrent episodes of elevated 
mood and depression accompanied by changes in activity levels. Based on DSM-IV, BD 
type 1 is featured as alternating episodes of depression and mania, whereas BD type 2 is 
characterized by depression and hypomania. Other related diagnoses include cyclothymia, 
characterized by hypomania and subthreshold depression, and bipolar disorder not otherwise 
specified. Manic and depressive symptoms can also co-occur, so called “mixed states”[12]. 
Rapid cycling is a severe subtype of BD defined as four or more bipolar episodes per year, 
which is associated with treatment resistance and overall poorer prognosis [13]. BD affects 
~1-2% of the population and this causes tremendous economic burden [14; 15]. In contrast to 
unipolar depression, the heritability of BD is high, up to 70~80%, and overlaps with that of 
schizophrenia in a number of common variants alleles [16].  Lithium is the first-line mood 
stabilizer in treating BD [16] however treatment response varies considerably and there is no 
predictive biomarker available [17]. Some studies suggest that lithium responsive-BD may 
be a distinct subtype of BD with genetic difference, however this hypothesis requires more 
investigation [18; 19]. In the thesis constituent papers, the study has been primarily focused 
on BD type 1 patients which the majority of study materials are collected from.  
Novel Mechanisms in Depression: Focus on Telomere Biology and Epigenetic Regulation 
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                                                                                                     “I can't eat and I can't sleep.  
                                  I'm not doing well in terms of being a functional human, you know?”                                                                                                                                                                                                 
                                                                                     ― Ned Vizzini, It's Kind of a Funny Story 
                                                                                 Depression by Yu Chen. Beijing, China. 2015. 
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1.1.2 Etiology of depression 
Depression is a complex disorder, meaning that the etiology of depression is the interactive 
effects of multiple genes in combination with lifestyle and environmental factors, which is 
best summarized as a prototypical G×E interaction model [20]. Moreover, epigenetics 
provide a bridge through which environment can affect the genome and play considerable 
roles in the pathophysiology of depression and antidepressant action [21]. In this section, 
neuroanatomy and related theories of depression studied in the constituent papers are 
provided, including the monoamine hypothesis, the neurotrophins and neurogenesis 
hypothesis, the hypothalamic-pituitary-adrenal axis and stress response theory and the 
inflammation theory of depression. Other theories such as glutamate hypothesis of 
depression and circadian abnormality hypothesis of depression also received great attention 
from researchers. One should keep in mind that although these theories of depression have 
been debated for a long time, none of these theories sufficiently explains the 
pathophysiology and treatment of depression. 
1.1.2.1 Neuroanatomy of depression 
Depression is a disorder that involves several critical brain regions and associated circuits 
and neural pathways. Using brain imaging technologies, e.g. structural imaging (CT) and 
functional imaging (fMRI, PET), several brain regions in depressed patients have been 
identified with altered structures and activity. Specifically, reductions in grey-matter volume 
and glial density in the prefrontal cortex (PFC) and the hippocampus (HIP) have been 
implicated in depressed patients [22; 23]. Activity changes in depression is characterized by 
abnormalities in limbic system–cerebrocortical circuits with reduced activity in frontal 
cortical areas and hyperactivity in the amygdala [24; 25]. PFC and HIP are the two main 
brain regions investigated in the current thesis. PFC has been implicated in executive 
function, working memory, personality expression and moderation of social behavior [26-
28]. Patients with PFC lesion showed depressive symptoms, suggesting that PFC is both 
critically and causally involved in depression [29]. HIP plays pivotal roles in cognitive 
function [30], mood regulation and memory formation [31]. In particular, substantial 
literature shows existence of adult neurogenesis in the subgranular zones of dentate gyrus in 
HIP [32] and the role of reduced neurogenesis in the pathophysiology of depression [33; 34]. 
1.1.2.2 The monoamine hypothesis of depression 
The monoamine hypothesis of depression posits that depression is caused by a depletion of 
the monoamine neurotransmitters in the central nervous system, such as serotonin, 
norepinephrine or dopamine which structurally contain one amino group connected to an 
aromatic ring by a two-carbon chain [35]. In accordance with this theory, almost all 
established antidepressants act either by inhibiting neuronal reuptake of monoamines that 
leads to an increased concentration in the synaptic cleft (e.g. SSRIs such as fluoxetine) or by 
hindering the degradation of monoamines (e.g. MAOIs such as tranylcypromine). Although 
SSRIs and MAOIs are potent antidepressants, full and partial resistance to these drugs and 
their delayed onset of action suggest the cause of depression is far from being a simple 
Novel Mechanisms in Depression: Focus on Telomere Biology and Epigenetic Regulation 
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deficiency of central monoamines. Although it is not particularly studied in the thesis 
constituent papers, the monoamine hypothesis is regarded as the most clinically relevant 
neurobiological theory of depression. 
1.1.2.3 Neurotrophins and neurogenesis hypothesis of depression. 
Reduced volume in hippocampus and other forebrain regions in subsets of depressed patients 
have supported a popular hypothesis for depression, involving a decrease in neurotrophic 
factors −− a family of proteins that are responsible for the growth, maintenance and survival 
of neurons that also regulates plasticity of mature neurons within the adult brain [36]. These 
events may be causally linked via neurogenesis [37]. One of the most studied neurotrophic 
factors, also the one investigated in the thesis, is brain-derived neurotrophic factor (BDNF) 
which has been shown to play a key role in the regulation of neurogenesis in the 
hippocampus and to have antidepressant-like effects [38; 39]. A number of studies, both 
preclinical and clinical evidence, have supported the theory that precipitating factors such as 
chronic stress may decrease the BDNF neurotrophic support, which leads to significant 
atrophy of the hippocampus. This is detrimental to hippocampal function and ultimately 
leads to the development of depressive symptoms [40-43]. However, considerable studies 
have generated inconsistent data which reminds us to reassess this theory [44; 45]. A role of 
BDNF supported by more consistent reports is that in antidepressant treatment, which could 
be beneficial to the development of novel antidepressant drugs [46].   
1.1.2.4 Dysregulation of the hypothalamic-pituitary-adrenal axis and stress response 
Stress is commonly defined as a state of real or perceived threat to homeostasis. In order to 
maintain homeostasis and to increase the probability of survival, animals activate a complex 
set of behavioral and physiological responses involving the nervous, endocrine, and immune 
systems which are collectively known as the stress response [47; 48]. Numerous studies have 
linked stress and depression, as depression may be a cause and/or outcome of chronic stress 
and increased stress levels can significantly affect the duration and degree of symptoms of 
depression [49]. Psychosocial stressors implicated in depression includes e.g. early life 
adversities, divorce or serious marital conflict and death of a relative [50; 51]. The principle 
anatomical structures that mediate the stress response is commonly referred to as the 
hypothalamic-pituitary-adrenal (HPA) axis (Figure 1) [52]. Activation of the HPA axis will 
lead to the release of glucocorticoids, which exert profound effects with their receptors on 
several somatic organ systems and brain regions. A negative feedback loop exists where high 
glucocorticoid levels dampen the HPA-axis activity  inhibits the secretion of ACTH from the 
pituitary and CRH from the hypothalamus [53]. Glucocorticoids are reported to regulate 
neuronal survival, neurogenesis and the sizes of hippocampus [54] and the two main 
receptors that are widely expressed in the brain include the mineralocorticoid receptor (MR) 
and the glucocorticoid receptor (GR). A number of studies have reported that depressed 
patients have HPA axis hyperactivity and increased levels of cortisol in the saliva, plasma 
and urine [55]. The increased activity of the HPA axis is thought to be related, at least in part 
due to an impairment of GR-mediated negative feedback (glucocorticoid resistance) [56]. In 
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agreement with this notion, abnormal GR and GR-associated protein expression (through 
both genetic and epigenetic mechanisms) have been implied in the brain of depressed 
individuals and GR is suggested to be a target for antidepressant action [55; 57-59]. 
                         
1.1.2.5 The inflammation theory of depression 
Increasing evidence suggests that activation of the immune system may play a critical role in 
the pathophysiology of depression. Increased levels of inflammatory biomarkers, including 
proinflammatory cytokines (such as TNF-α, IL-6 and IL-1β), acute phase proteins and 
chemokines have been reported in depressed patients [60; 61]. In addition to association 
between inflammatory markers and depression, several studies also demonstrate that both 
acute and chronic administration of cytokines (or cytokine inducers such as 
lipopolysaccharide or vaccination) can cause depressive symptoms [62; 63] and anti-
inflammatory therapy may have clinical benefit for depressed patients [64; 65]. Cytokines in 
the periphery have been shown to access the brain by several routes and can interact with a 
number of pathophysiological domains involved in depression, including neurotransmitter 
metabolism (serotonin, norepinephrine, and dopamine), neuroendocrine function (HPA axis), 
and neural plasticity (neurotrophic support, neurogenesis and glutamate transportation) [66]. 
However, it remains unclear whether activation of inflammation pathways during depression 
originates primarily in the periphery or in the central nervous system. The source of immune 
activation in depression can be quite diverse, nevertheless, psychosocial stress has been 
regarded as a major factor particularly in medically healthy depressed individuals, which can 
activate the inflammatory response both peripherally and in the brain [67; 68]. 
1.1.3 Genetics and depression 
Genetic components are considered to be important in the development of depression, as 
indicated by genetic epidemiology data from family and twin studies, and may provide 
important evidence about disease mechanisms. Family studies estimate that there is 
Novel Mechanisms in Depression: Focus on Telomere Biology and Epigenetic Regulation 
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approximately threefold increase in lifetime risk of developing depression among first-
degree relatives of depressed probands [69]. Twin studies suggest a heritability of depression 
to be 37% and it is significantly higher in women than in men [69; 70]. Familial aggregation 
coupled with the high heritability of depression led to optimistic thoughts that molecular 
genetic techniques would reveal risk gene variants that have substantial influence on 
depression. Unfortunately, from linkage studies, candidate gene studies to genome-wide 
association studies, the process of identifying those gene variants have been slow and the 
results have been difficult to consistently replicate so far [71]. The possible explanation 
could be that depression is a complex and heterogeneous disorder where each susceptibility 
gene variant contributes only a small fraction of the overall genetic risk. In order to 
overcome these problems, increase of sample size and categorization by subtype of 
depression are among the most recommended suggestions [72]. Despite these obstacles, 
some promising and reproducible genetic findings have been generated using G x E model 
which incorporates environmental risks, such as the study of interaction effect of stressful 
life events and the variants in the serotonin system [73]. 
1.1.4 Epigenetics and depression 
The term ‘epigenetics’ was initially coined by Waddington in the 1940s to address the 
question of how numerous distinct cell types were generated from the same genome [74]. 
The definition of epigenetics has changed over time, and now it refers to a stably heritable 
(mitotically and/or meiotically) phenotype resulting from changes in a chromosome without 
alterations in the DNA sequence [75]. By this definition, epigenetic markers mainly include 
DNA methylation and histone modifications. However, previously the definition of 
epigenetic modifications included also the effect of noncoding sequences such as 
microRNAs (miRNAs) [76]. Epigenetics has provided a mechanism by which environmental 
factors can affect chromatin structure that ultimately lead to persistent alteration in gene 
expression. Accumulating evidence suggests critical roles of epigenetic mechanism in 
neuronal plasticity, neurogenesis and neurological and psychiatric disorders [77; 78]. 
Epigenetics may help to explain some of the missing heritability in depression and provide 
new insights to understand the pathophysiology [79]. In the present thesis, two types of 
epigenetic modifications are investigated in relation to depression: DNA 
methylation/hydroxymethylation and miRNAs.  
1.1.4.1 DNA methylation 
DNA methylation was described as early as in 1948 [80], but it was not until 1969 that 
Griffith and Mahler suggested that these modifications may modulate gene expression [81]. 
DNA methylation includes methylation of cytosine (predominant form in mammals), 
adenine and guanine [82] and the primary form of mammalian methylated cytosine is in the 
context of CpG dinucleotides (5-methylcytosine, 5mC); 70 – 80% of CpGs are methylated. 
There is increasing evidence showing that cytosines in non-CpG sequences (i.e. CpH, 
H=A/T/C) are also frequently methylated, especially in the brain [83; 84]. In mammals, 
DNA methylation patterns are initially established by the de novo DNA methyltransferases 3 
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family (DNMT3A/3B) and maintained during cell division by the maintenance 
methyltransferase (DNMT1) which prefers hemi-methylated DNA [85; 86]. Although DNA 
methylation has been regarded as a stable epigenetic mark, growing evidence indicates that 
DNA demethylation can occur through both passive and active mechanisms [87]. Passive 
DNA demethylation refers to the loss of 5mC during DNA replication in the absence of 
functional DNMT1. By contrast, active DNA demethylation requires an enzymatic process 
which removes or modifies 5mC by ultimately breaking the carbon-carbon bond. A number 
of enzyme has been characterized recently which includes the ten-eleven translocation 
protein family (TET1-3), facilitating the oxidation of 5mC to 5-hydroxymethylcytosine 
(5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) [88]. The following 
demethylation process is often coupled with thymine DNA glycosylase (TDG)-mediated 
base excision repair (BER) pathways and deaminases which lead to unmodified cytosine (C). 
A brief summary is shown in Figure 2. Currently, it is generally accepted that cytosine 
methylation regulates gene transcription in a highly cell-type specific manner [89]. In 
general, a heavily methylated promoter region corresponds to inactive transcription. This 
gene silencing mechanism is thought to either be due to direct inhibition of transcription 
factor binding by DNA methylation or mediated by methyl-binding domain proteins that 
recruit various co-repressor complexes to methylated DNA [90]. 5hmC is regarded as an 
intermediate of demethylation, however the relatively high steady-state levels of 
5hmCsuggest that 5hmC might also function as a stable signal that modulates binding of 
protein complexes to chromatin thus influences gene expression [91; 92]. In the present 
thesis, both 5mC and 5hmC were studied with a specific investigation of the Bdnf gene [93]. 
Other established functions of DNA methylation involves multiple cellular processes, such 
as DNA–protein interactions, cellular differentiation, transposable elements suppression, 
embryogenesis, X-chromosome inactivation and genomic imprinting [94; 95].  
 
1.1.4.2 MiRNA 
MiRNAs are small, ~22 nucleotides long, non-coding RNAs that typically function as key 
post-transcriptional repressors of gene expression [96]. The biogenesis and expression of 
miRNAs is under strict temporal and spatial control and is involved in nearly all 
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developmental and pathological processes. Dysregulation of miRNAs have been associated 
with many human diseases including depression [97]. Most miRNAs derive from 
transcription of primary transcripts (pri-miRNAs) by RNA-PolII in the cell nucleus. Primary 
transcripts are processed by DROSHA/DGCR8 heterodimer into 60-80 nucleotides (nt) long 
precursors miRNAs (pre-miRNAs) which are released into cytoplasm. DICER together with 
its dsRNA-binding partner TRBP, further cleave pre-miRNAs into an approximately 22 nt 
double stranded mature miRNAs. Supported by the HSC70–HSP90 chaperone machinery, 
only one strand of the mature miRNA is incorporated into the RNA-induced silencing 
complex (RISC) while the other strand is degraded. The miRNA-RISC complex regulates 
target mRNA expression through mRNA degradation and/or translational repression [98]. A 
few miRNAs are produced by alternative pathways e.g. the ‘mirtron pathway’ that replaces 
standard miRNA biogenesis steps [99]. In the present thesis, the lethal-7 (let-7) miRNA 
family is for the first time investigated in the FSL/FRL rat PFC region, a study which 
focused on LIN28B-mediated biogenesis dysregulation. The let-7 family is highly conserved 
between species and consists of 12 genes encoding 9 distinct miRNAs (let-7a to let-7i and 
miR-98) [100]. There is increasing evidence suggesting the involvement of the let-7 family 
in inflammation and immune response, and the let-7 family has also been implicated in 
neuronal proliferation and differentiation and synaptic plasticity [101-104]. However, its role 
in relation to the pathophysiology of depression is less investigated. 
1.1.5 Telomere biology and depression 
Mammalian telomeres are protective DNA-protein structures located at the end of 
chromosomes. They shorten progressively during each cell division due to incomplete 
replication of linear chromosomes by conventional DNA polymerases, which often referred 
to as ‘end-replication problem’ [105]. Then a natural question is that by which mechanism 
telomeric DNA is maintained. This was answered by Blackburn and Greider who showed 
that telomeric DNA is synthesized by telomerase, being capable of compensating for this 
progressive telomere attrition [106]. One may also wonder how cells distinguish their natural 
chromosome ends from double-strand breaks elsewhere in the genome, i.e. how do cells 
solve the ‘end-protection problem’. Shelterin is one of the most important and well-
characterized telomere-associated protein complexes that are involved in protecting the 
chromosome ends from two DNA damage signaling pathways (ATM and ATR mediated cell 
cycle arrest) and two double-strand break repair pathways (NEHJ mediated chromosome 
fusion and HDR mediated chromosome recombination) [107]. In this section, telomere 
length and telomerase in relation to depression research are introduced. 
1.1.5.1 Telomere length shortening in depression 
Telomeres consist of tandem repeat DNA sequences (TTAGGG) and protective proteins.  
The telomeres are responsible for preventing the chromosome ends from activation of DNA 
damage response pathways and improper repair pathways [108]. Telomeres are shortened 
during every cell division, and critically shortened telomeres result in loss of telomere 
protection which lead to cell cycle arrest and apoptosis pathways. The length of telomeres is 
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suggested to indicate biological aging [109]. In recent years, a number of studies have 
reported shorter blood leukocyte telomere length (LTL) to be associated with depression, and 
the shorter LTL the more experienced depressive episodes in bipolar disorder [110-116], 
implying that depressive individuals may bear increased risk of dysfunctional telomeres and 
biological aging-related decline. For example, an average shortening corresponding to 6-10 
years of accelerated biological aging has been estimated in blood leukocytes of depressive 
patients [117; 118]. But only a few studies have investigated telomere length in depressed 
brains [119; 120]. Telomere shortening has also been associated with psychological stress, 
oxidative stress and inflammation [121-123]. Adversity in childhood has been associated 
with shorter LTL in adulthood [124; 125].  
1.1.5.2 Telomerase dysfunction in depression 
Telomerase is a reverse transcriptase that consists of a catalytic reverse transcriptase subunit 
(TERT) and an RNA component (TERC) being template for DNA synthesis. Telomerase 
adds TTAGGG repeats to the chromosome ends and thereby counteracts the telomere 
shortening [126]. High level of telomerase expression is found in pluripotent stem cells, early 
stages of embryonic development and cancer cells, although telomerase activity is also 
present in normal adult stem cell compartments, such as lymphocytes in the bone marrow 
and peripheral blood, a subset of proliferating epithelial cells in the skin, the hair follicle, the 
gastrointestinal tract and endometrium and a subset of cells in the testis [127]. There is also 
detectable telomerase in adult brain regions where neurogenesis exists: the subgranular zone 
of the dentate gyrus in hippocampus and the subventricular zone of lateral ventricle. In 
addition to adding nucleotide repeats, telomerase has been reported to be involved in cellular 
protection and plasticity [128; 129]. In the murine hippocampus, inhibition of TERT 
expression induced neuronal excitotoxicity, apoptosis and a depressive-like behavior [130; 
131], and in humans, telomerase activity in peripheral blood leukocytes associated positively 
with hippocampal volume of postmortem brains from depressed individuals [132]. Further, 
reduced hTERT expression was found in oligodendrocytes of white matter from postmortem 
depressed brains compared to corresponding tissue from control brains [120]. Accordingly, 
TERT overexpression was associated with [133] and promoted [134] adult neurogenesis, and 
the antidepressant fluoxetine upregulated telomerase activity [134]. 
1.1.6 Treatment 
First-line treatment for moderate to severe depressive disorders includes pharmacotherapy 
(i.e. antidepressants such as SSRIs [135]), psychotherapy (e.g. cognitive behavioral therapy 
[136]), or a combination of both. Next-step treatment recommendations are switching drug 
or augmentation (e.g. in combination with lithium, antipsychotics or ECT), depending on 
patients response to the initial treatment. Maintenance therapy continues the approach that 
led to remission [137]. However, these medications are facing a number of difficulties, with 
a substantial proportion of patients showing poor clinical response and suffering from 
residual symptoms and side-effects. It also takes weeks to months before those drugs achieve 
clinical benefits [138]. Thus, there is a clear and urgent need for the development of novel  
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antidepressants with robust efficacy. For example, clinical trials have shown that ketamine 
acts rapidly and effectively for treatment-resistant depression patients and may serve as a 
novel antidepressant [139]. Pre-clinical evidence also suggests drugs targeting epigenetic 
mechanism such as sodium butyrate (NaB) and L-acetylcarnitine, which exhibit promising 
antidepressant-like effect in animal model [93; 140]. In addition, physical exercise, a non-
pharmacological intervention, has been shown to alleviate depressive symptoms in persons 
affected by mild to moderate depression [141]. Molecular mechanism of lithium, NaB and 
physical activity were investigated in the thesis constituent papers in relation to depression 
therapy.  
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2 AIMS 
The overall aim of the thesis is to increase the understanding of the pathophysiology of 
depression with a focus on telomere biology and epigenetic regulation. Such information 
may be critical in providing both preclinical and clinical evidence to develop better 
diagnostic markers and therapeutic approaches. 
The specific aims of each constituent study in the thesis were listed below: 
Study I To test whether lithium treatment in bipolar patients may influence blood 
leukocyte telomere length (LTL) and whether LTL may associate with 
lithium responsiveness, number of depressive episode as well as rapid 
cycling feature of bipolar patients. 
Study II Based on the findings in study I, we used a genetic rat model of depression 
(FSL) to investigate whether telomere length was shorter, telomerase activity 
was changed in the depressed brain with a focus on the hippocampus region, 
and whether lithium treatment could reverse such processes.  
Study III Based on the findings in study I and II, we investigated whether telomere 
length was shorter in adult depression by using less-invasive saliva DNA 
samples and whether genetic variation in the functional subunit of telomerase 
(hTERT) was associated with depression and number of depressive episodes 
in bipolar disorder type I. 
Study IV To examine histone deacetylase inhibitor NaB’s putative antidepressant-like 
efficacy in relation to DNA methylation changes in the prefrontal cortex 
region of FSL rat model of depression. 
Study V To investigate whether the FSL rat model of depression had elevated levels 
of the proinflammatory cytokine Il6 in the PFC region and whether this 
inflammation state was associated with disturbed miRNA let-7 expression, in 
turn influenced by alterations in miRNA biogenesis. We then explored if 
physical exercise would lower the elevated Il6 levels in the PFC region of the 
FSL rats, through the rescue of let-7 expression.  
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3 MATERIALS AND METHODS 
In this section, an overview of the materials and methods used in the thesis’ constituent 
papers are introduced. If not otherwise stated, all generated data were analyzed using 
appropriate statistical methods. All experiments and materials were approved by relevant 
ethical committees. 
3.1 ANIMAL STUDY 
All animal studies in this thesis were performed by using a genetic rat model of depression-
like behavior: the Flinders Sensitive Line (FSL) and its controls, the Flinders Resistant Line 
(FRL). The animal studies included analyses of behavior tests and treatment effects, gene 
and protein expression, telomere length and telomerase activity, DNA/protein interaction and 
epigenetic modifications. 
3.1.1 The FSL genetic rat model of depression 
The FSL/FRL rats were generated as a genetic model by selective breeding towards 
sensitivity to the anticholinesterase agent diisopropyl fluorophosphate (DFP). Compared to 
FRL, the FSL is genetically more sensitive to DFP and partially resembles human 
depression, thus it is referred to as a depression-like model [142]. The FSL strain exhibits 
good face validity for depression (e.g. psychomotor retardation, reduced appetite/loss of 
weight, sleep disturbances, impaired emotional memory and immune abnormality), satisfies 
the criterion of construct validity (e.g. abnormal neurochemical systems including 
serotonergic, dopaminergic and neuropeptide Y), and has a high predictive validity for a 
number of either known antidepressant drugs (e.g. tricyclic and SSRI ) or novel drugs that 
have antidepressant effect potentially for later on use (e.g. sodium butyrate) [142; 143]. 
3.1.2 Behavior tests and treatments 
One type of behavior experiment and three types of treatment interventions were used. The 
behavior experiment performed was the behavioral despair test (a.k.a. the Porsolt forced 
swimming test; FST), which is commonly used to observe FSL’s exaggerated immobility 
(floating) behavior in a water cylinder that reflects a despair state analogous to human 
depression. FST is also a measure of effectiveness of antidepressants [144]. The expected 
antidepressant-like effect is a decrease of the immobility time after intervention. Three types 
of treatment interventions were introduced: oral administration of lithium, intraperitoneal 
(i.p.) injection of HDACi (sodium butyrate) and physical exercise (running wheel). 
3.1.3 RNA and protein analyses 
The RNA molecules included both coding (mRNA) and non-coding (miRNA and pri-
miRNA) RNA. The expression levels of  targeted RNA (converted into the form of 
complimentary DNA; cDNA) were detected primarily by using quantitative Real-Time PCR 
(qRT-PCR), which is a technique that simultaneously amplifies and quantifies cDNA [145]. 
The protein analyses were performed by immunoblotting (western blotting) using specific 
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antibody to detect and quantify targeted protein levels (e.g. TET1, BDNF, β-catenin, 
DROSHA and LIN28B)[146]. 
3.1.4 RNA and protein interaction analyses 
In order to investigate RNA/protein interaction related to LIN28B and pri-let-7 transcripts in 
vivo, RNA immunoprecipitation (RIP) was performed using PFC region from FSL/FRL rats. 
RIP involved tissue lysis, followed by an immunoprecipitation stage with an antibody that 
targeted LIN28B. After RNA-protein complexes were isolated by magnetic beads, the RNA 
of interest was purified, which then was followed by cDNA conversion and qRT-PCR 
quantification [147]. 
3.1.5 Telomere length and telomerase activity analyses 
Telomere length (TL) was determined as relative values using qRT-PCR technique by 
calculating the ratio of telomere repeat copy number to single copy gene copy number [148]. 
Based on the enzymatic property of telomerase, which is adding telomeric repeats 
(TTAGGG) to the chromosome ends, the real-time telomeric repeat amplification protocol 
(RT-TRAP) [149] was used to detect telomerase activity in the hippocampus region of 
FSL/FRL rats. 
3.1.6 Epigenetic analyses 
The epigenetic analyses included DNA methylation/hydroxymethylation (5mC/5hmC) and 
histone modification experiments. DNA methylation/hydroxymethylation analyses were 
performed both globally (producing an average value representing the whole genome) and 
within specific regions of the target genes. Global DNA methylation/hydroxymethylation 
was assessed using a sandwich-based ELISA method while region-specific DNA 
5mC/5hmC was assessed using a magnetic assay capable of isolating DNA fragments either 
with 5mC or a modified 5hmC. 
3.2 HUMAN STUDY 
The human studies presented in this thesis were performed mainly from PART study and 
bipolar study. It includes genetic and telomere analyses. 
3.2.1 The PART study 
PART (Psykisk hälsa, Arbete, RelaTioner) is a longitudinal population-based study of 
mental health, work and relationships conducted in Stockholm County, Sweden. It started 
1998 and questionnaires were sent out to individuals randomly selected from Stockholm city 
council registers. The questionnaire includes demographic, socioeconomic and somatic 
health data, negative life events, smoking, illicit drug use and screening instruments for 
psychiatric disorders including the Major Depression Inventory (MDI), Sheehan Patient-
Rated (Panic) Anxiety Scale, the Yale-Brown Obsessive-Compulsive Scale, symptoms of 
social phobia and agoraphobia according to Marks and Mathews (1979), eating disorders 
according to Beglin and Fairburn (1992), the World Health Organization Short Disability 
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Assessment Schedule (WHO DAS-S) and hazardous alcohol use according to Alcohol Use 
Disorder Identification Test (AUDIT). Epidemiological data have so far been collected three 
times: wave I (1998-2000), wave II (2001-2003) and wave III (2010-2011). A subgroup of 
individuals were selected for psychiatric interviews using Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN) by experienced psychiatrists and one psychologist. During the 
period 2006-2007, saliva DNA were asked for from 5527 PART II participants including all 
individuals with a depression or anxiety diagnosis and a random number of individuals who 
had no psychiatric diagnosis or psychopathological symptoms in any of the two waves. 
Blood samples were collected in a subgroup of individuals, which yielded in total 88 
samples. The schematic chart with detailed number of participants is shown below. For more 
information about PART study see Hällström et al [150] and www.folkhalsoguiden.se. 
 
3.2.2 The bipolar study 
Patients with a clinical diagnosis of bipolar disorder (BD) were consecutively recruited from 
the Unit of Affective Disorders at Psychiatry Southwest, Huddinge Hospital, Stockholm. 
Life-time manic and depressive symptoms were assessed by a psychiatrist specialized in BD 
or by a trained psychiatric nurse using the modules for mania and depression in the SCAN. 
On the basis of these assessment patients were considered as fulfilling the diagnostic criteria 
for BD type 1, 2, or not otherwise specified (NOS). The symptoms as well as the number of 
manias and depressive episodes, rapid cycling and mixed episodes were assessed, including 
the age of onset of mania and depression. Lithium response was measured according to the 
Alda-Scale. In previous studies, lithium responders (LiRs) were those who scored ≥ 7 and 
non-LiRs were those who scored ≤ 6 (range 0–10 points) [151]. 
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3.2.3 Genetic and telomere analyses 
Genetic analyses were performed for single nucleotide polymorphism (SNP) in human TERT 
gene (rs2736100 A/C). SNP genotyping utilized TaqMan assay, which was a PCR-based 
reaction that amplified the region included the SNP site. Allele discrimination is achieved 
using probes linked to fluorophore at 5’ end and a quencher molecule at 3’ end [152]. During 
the PCR amplification, if the allele-specific probe is perfectly complementary to the SNP 
allele, the fluorophore would separate from the quencher due to degradation by 5’-nuclease 
activity of the Taq polymerase, generating a detectable signal that could be read in qRT-PCR 
machine. Based on the conservation of telomere sequence between mammals (TTAGGG 
tandem repeat) [153], the method used for human telomere analyses was the same as rats, 
which was described in section 3.1.5 with minor modification.  
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4 RESULTS AND DISCUSSION 
In this section, the major findings are integrated from the thesis constituent papers. More 
details and comprehensive descriptions are given in the full papers which could be found in 
the back of the printed thesis. 
4.1 TELOMERE DYSFUNCTION IN HUMAN DEPRESSION 
4.1.1 Shorter saliva telomere length in self-reported adult depression 
To date, most of the reports on telomere length (TL) in depression have been performed on 
peripheral blood leukocytes. In paper III, we used whole saliva DNA, a less invasive DNA 
source, and showed that adults with a history of depression had shorter TL compared to age-
matched controls, by using samples (n = 662) from the PART cohort. In this analyses, a 
number of parameters previously reported to be associated with LTL were adjusted for 
including age, sex, alcohol use, number of somatic diseases and number of childhood 
adversities. In agreement with, and supported by previous studies, the majority of DNA 
extracted from whole saliva actually originates from blood leukocytes, which is different 
from buccal cell collection techniques [154; 155]. 
4.1.2 Telomere length associated negatively with increasing number of 
depressive episodes in bipolar disorder 
In paper I, a significant effect of number of depressive episodes on blood leukocytes 
telomere length (LTL) was found in bipolar disorder (BD) patients. Specifically, the LTL 
marginal mean was reduced 0.075 units per depressive event after adjusting for age and sex 
in the linear model. This effect was stronger in males than in females. This is in line with the 
only previous study of TL in BD, which found that BD type 2 and number of depressive 
episodes were associated with shorter LTL however in a smaller sample size [116]. 
4.1.3 Rs2736100 polymorphism is associated with depression and the 
number of depressive episodes in bipolar disorder type I 
SNP rs2736100, located in the intron 2 of the hTERT gene, was previously associated with 
shorter LTL through the risk allele A in a genome-wide meta-analysis [156]. In paper III, we 
tested the hypothesis that rs2736100 associates with depression in PART cohort. There was 
no association between rs2736100 genotype and depression in the whole material (n = 2026), 
adjusted for age, sex, and experience of childhood adversity. However when stratified for 
childhood adversity, an established risk factor for depression in adulthood [157; 158], 
homozygosity for the ‘short LTL’-risk allele A was significantly associated with higher risk 
of depression compared to the AC/CC genotypes in the group without experience of 
childhood adversity (rs2736100: P = 0.010, OR = 1.51, 95% CI = 1.10-2.05; sex: P < 0.001; 
age: P = 0.007). That this relationship was detected only in those without experience of 
childhood adversity might be explained by the fact that early adversity has previously been 
associated with depression and shorter LTL in adulthood [124; 125; 159; 160]. Hence, early 
adversity might conceal an rs2736100-depression relationship. 
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We and others previously showed that LTL was associated with the number of depressive 
episodes and lithium response in BD [115; 116]. We tested whether SNP rs2736100 
associated with the number of depressive episodes within BD1, considering the patients’ 
response to lithium treatment. In patients responding well to lithium treatment (LiR), the risk 
allele A showed dominance, that is the AA/AC genotype significantly associated with higher 
number of depressive episodes compared to the CC genotype (AA/AC vs CC: F = 10.9, P = 
0.001; sex: F < 0.001, P = 1.00; years since onset of first depressive episode: F = 16.8, P < 
0.001; age: F = 0.36, P = 0.55; ANCOVA). We also observed a similar effect in A/C allelic 
model, with the A allele conferring a risk for increased number of depressive episodes. That 
the finding in BD patients was confined to the LiR group may reflect a possibly higher 
lithium functionality in the LiR group, and the fact that lithium upregulates hTERT [161], 
which in turn may upregulate the functionality of rs2736100. 
4.2 TELOMERE DYSFUNCTION IN THE FSL RAT MODEL OF DEPRESSION 
4.2.1 Shorter hippocampal telomere length in the depressed FSL rat model 
Shorter telomeres in leukocytes were reported to be associated with major depression. 
However, it is not clear whether the same holds true for the respective brains. A study from 
Szebeni et al showed that oligodendrocytes but not astrocytes from depressed individuals 
displayed shorter TL and decreased TERT expression compared to corresponding 
postmortem white matter (frontal and temporal lobes) from control brains [162]. Since 
hippocampus is pivotal in cognitive function [30], mood regulation and memory formation 
[31] and it is a region that expresses telomerase activity also in adulthood, in paper II we 
tested whether there is telomere dysfunction in the hippocampus of the depressed FSL rat. 
We found that the FSL had shorter hippocampal TL compared to the control line FRL.  
4.2.2 Decreased Tert and telomerase activity in the FSL hippocampus 
Shorter telomeres may result from a decreased telomerase activity. The expression of the 
catalytic subunit (TERT) of telomerase is stringently regulated, and of the several splicing 
forms the full length mRNA correlates positively with telomerase activity [163; 164]. The 
Tert transcript is highly conserved between human and rodents [164], thus enabling 
translational studies in rodent models. In paper II, we explored if the shorter TL in the FSL 
hippocampus could reflect a reduced telomerase activity. The Tert levels were reduced in the 
FSL compared to the FRL rats. Consistent with the downregulated Tert expression, 
telomerase activity was lower in the depressed FSL hippocampi. Telomerase overexpression 
has been suggested to promote adult neurogenesis in the hippocampus [133; 134]. 
Substantial literature shows existence of adult neurogenesis, particularly in the dentate gyrus 
[32] and the role of reduced neurogenesis in the pathophysiology of depression [33; 34]. 
Interestingly, chronic mild stress in mice resulted in decreased TERT levels and telomerase 
activity as well as reduced neurogenesis in hippocampus and a depression-like behavior. In 
contrast, fluoxetine and intrahippocampal infusion of 3-azido-deoxythymidine (AZT) 
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reversed these effects leading the authors to suggest that hippocampal telomerase plays a role 
in depression-like behaviors, possibly by regulating neurogenesis [134]. 
4.3 INFLUENCE OF LITHIUM TREATMENT ON TELOMERE LENGTH AND 
TELOMERASE ACTIVITY 
4.3.1 Longer telomere length in bipolar patients and good Li-responders 
In paper I, we found that LTL correlated positively with length of lithium treatment (duration 
≥30 month) in BP patients. We also found significantly longer LTL in BP patients (n = 202) 
when compared to healthy controls (n = 135). This significance could also be seen in lithium 
monotherapy (n = 39) in comparison with healthy controls. Furthermore, LTL seemed to 
reflect lithium response indicated by that those with good response (LiR, n = 31) had 10% 
longer LTL compared with those with no or partial response (non-LiR). 
4.3.2 Lithium increases Tert and telomerase activity in the FSL 
hippocampus 
In paper II, we tried to explore the mechanism how lithium protects against TL shortening. 
We conducted a 6-week treatment with either Li2SO4 or vehicle admixed to the FSL rat 
chow. Both Tert expression and telomerase activity were increased in the hippocampi from 
the lithium treated FSL (FSL-Li) compared to the FSL-vehicle group. But hippocampal TL 
was not statistically increased in FSL-Li group. A similar lack of TL change despite 
telomerase upregulation was also reported by Wolkowitz et al [114]. Explanations could be 
that TL changes much slower than telomerase activity [165; 166]; our previous study found 
that long-term lithium treatment (≥30 months) in patients diagnosed with bipolar disorder 
correlated positively with LTL [115].  
4.3.3 Potential mechanism of lithium’s effect on telomere biology  
Lithium was previously shown to inhibit GSK-3β [167], which results in retention of β-
catenin [168]. Lithium-induced upregulation of β-catenin was shown to upregulate hTERT 
transcription in cancer cell lines [169] however no such studies have been done in the brain 
region. Lithium has also been reported to promote expression of BDNF which, in turn, 
enhances Tert expression [170]. In addition, BDNF was reported to modulate telomerase 
activity in embryonic hippocampal neurons [170], In paper II, we investigated levels of 
putative mediators, β-catenin and BDNF, of lithium’s effect on telomerase activity, both in 
naïve FSL/FRL and FSL-vehicle/FSL-Li groups. We found decreased BDNF levels in naïve 
FSL compared to FRL, which may in part underlie the reduced telomerase activity in FSL 
brain. But we didn’t see any level difference in β-catenin between naïve rats. Interestingly, 
when we measured the β-catenin levels in FSL-Veh and FSL-Li hippocampi, β-catenin 
levels were significantly higher in the FSL-Li group, but lithium didn’t seem to influence 
BDNF levels. The duration of lithium treatment has been implied to influence BDNF 
changes, e.g. an increase in BDNF was found after 14 days, but not 28 days, while the 
treatment duration in our study was 42 days [171].  
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4.4 EPIGENETIC FINDINGS IN THE FSL RAT MODEL 
4.4.1 Sodium butyrate affects DNA methylation in the FSL prefrontal cortex 
(PFC) 
The epigenetic drug sodium butyrate (NaB) showed antidepressant-like effects in preclinical 
studies [172; 173]. Research has focused on its role as a histone deacetylase inhibitor, but 
there is also evidence that NaB affects DNA methylation [174-176]. In paper IV, chronic 
intraperitoneal administration of NaB had antidepressant-like effects in the FSL and was 
accompanied by increased levels of TET1 in the PFC region. Hydroxylation of 5-
methylcytosine (5mC) by TET proteins were previously shown to lead to the formation of 5-
hydroxymethylcytosine (5hmC), which can then mediate active DNA demethylation [177-
179]. This mechanism has important implications for studies of postmitotic tissues where 
cell division and DNA replication have ceased, such as the brain region we studied here. In 
addition, 5hmC has been found to be most abundant in the brain where it is particularly 
enriched in active genes, indicating a crucial role for this DNA modification in neuronal gene 
expression and memory formation [92; 180]. In paper IV, the TET1 upregulation was 
associated with an increase of 5hmC and a decrease of 5mC in Bdnf gene. These epigenetic 
changes were associated with a corresponding BDNF overexpression. These findings are in 
line with two recent studies showing that TET1 overexpression in the mouse hippocampus 
also leads to increased Bdnf expression [177; 180]. 
4.4.2 Inflammation and disturbed let-7 biogenesis in the FSL prefrontal 
cortex 
Elevation of the proinflammatory cytokine IL-6 has been implicated in depression, however 
the mechanism remains elusive [181-183]. Previous study showed that let-7 family directly 
inhibited IL-6 expression, which may act as an immunorepressor [184]. In paper V, we 
found elevation of Il6 in PFC region of FSL, which was associated with overexpression of 
LIN28B and downregulation of let-7 miRNAs (including let-7b, let-7c, let-7f, let-7i and 
miR-98). LIN28B is an RNA-binding protein that selectively represses let-7 synthesis. Also 
DROSHA, key enzyme in miRNA biogenesis, was downregulated in the FSL PFC. The let-7 
family plays an important role in early neurodevelopment. However, other roles of let-7 
family in the adult brain have been less investigated despite the fact that let-7 is known to be 
upregulated in later developmental stages and is one of the most abundant miRNA families 
in the adult brain [185; 186]. Thus, the results indicate upregulated Il6 levels in FSL PFC by 
let-7 downregulation through LIN28B and DROSHA dysregulation. Let-7 can also inhibit 
LIN28B translation by binding to the 3′ UTR target sites, creating a double negative 
feedback loop [187]. Noteworthy, let-7 could also be regulated in a LIN28B-independent 
way, e.g. through epigenetic mechanisms such as DNA and histone methylation [188]. It is 
possible that let-7 dysregulation can lead to disturbances also in other pathophysiological 
processes because a miRNA often has multiple target genes. The fact that we observed that 
FSL PFC had decreased DROSHA levels, suggests a disturbed miRNA biogenesis probably 
not only in let-7 but also in a variety of other miRNAs. In line with this hypothesis, a recent 
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study has demonstrated a general reduction of miRNA expression in the PFC from depressed 
suicidal subjects [189]. Previous studies have shown that physical activity in the form of 
wheel-running exerts antidepressant-like effect in the FSL rat model [190; 191]. We found 
that physical activity reduced Il6 levels and selectively increased let-7i and miR-98 
expression in the FSL PFC, which were independent of Lin28b and Drosha changes. 
However, upstream primary miRNA transcription was increased in the FSL-runners, 
implying that other mechanisms (e.g. epigenetic) are involved in regulating let-7 expression 
in response to physical activity. 
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5 SUMMARY AND CONCLUDING REMARKS 
In this section a summary of conclusions from each constituent paper, as well as general 
concluding remarks, are provided. 
 In bipolar patients, long-term lithium treatment was suggested to protect against 
telomere shortening especially when therapeutically efficacious (i.e. in patients who 
responded well to lithium). The shorter telomere length associated with a history of 
higher number of depressive episodes (Paper I).    
 Shorter telomere length and dysfunctional telomerase activity in hippocampus was 
associated with a depression-like state in the FSL rat. Lithium treatment  normalized 
the hippocampal telomerase dysfunction, possibly through the activation of β-catenin 
(Paper II). 
 Saliva telomere length was decreased in adult individuals with a history of depression 
and genetic variation in hTERT may influence the susceptibility to depression (Paper 
III). 
 Sodium butyrate exerted antidepressant-like effect in the FSL and the suggestive 
epigenetic effects of sodium butyrate may include DNA methylation changes that are 
mediated by demethylation-facilitating enzymes like TET1 (Paper IV). 
 Elevation of proinflammatory cytokine Il6 in prefrontal cortex region of the FSL was 
associated with disturbance of let-7 family biogenesis. Physical activity could reduce 
the cortical Il6 levels possibly through regulating miRNA expression (Paper V).  
 
Depression is a complex disorder with multiple genetic, epigenetic, behavioral and 
environmental risks that contribute to the heterogeneity of the illness. The understanding of 
the pathophysiology of depression has evolved substantially over years and researchers have 
realized the importance of utilizing multidisciplinary approaches to unravel the 
neurobiological bases for depression. Focusing beyond the traditional pathophysiological 
theories of depression, telomere biology may provide new insights to the development of 
predictive markers for depression and to the understanding of the neuroprotective effects of 
lithium. Expanding the knowledge about epigenetic dysregulations in depression may 
provide novel mechanism and therapeutic possibilities. In addition to some psychotropic 
drugs with epigenetic effects e.g. valproic acid, there are many epigenetic drugs that have 
lately received much attention, however still more preclinical and clinical support is needed 
before targets in psychiatric disorders are identified.   
In summary, the studies in this thesis work contribute to increase the understanding of 
molecular mechanisms in depression and mood disorder treatment.   
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6 FUTURE PERSPECTIVES 
A number of questions, related to the results in the studies of this thesis, remains to be 
answered. Here, the major perspectives for future work are listed. 
 The telomere length and telomerase activity were measured in a homogenate of 
hippocampus tissue which may include neurons, glia, vascular and immune cells. 
Since cell types exhibit different telomere vulnerability towards cellular stress, it is 
important to investigate telomere dysregulation at a cell-type specific level.  
 The causal relationship of the association between dysfunctional telomeres and 
depression symptoms is elusive. Support from additional human studies that genetic 
variation in hTERT associates with depression and the number of depressive episode 
in bipolar disorder would suggest that telomerase activity influences the risk for 
depression and the number of depressive episodes in bipolar disorder.  
 Leukocyte telomerase activity was reported to correlate positively with SSRI 
responsiveness in depressed cases with low baseline telomerase activity [114], 
suggesting that telomerase activation might be beneficial in antidepressant treatment. 
The molecular mechanisms underlying leukocyte telomerase changes in response to 
SSRI is not clear. However, it was recently shown that leukocyte telomerase activity 
correlated with hippocampal volume, suggesting that this activity indexes a 
neuroprotection or neurogenesis in the hippocampus of depressed individuals, 
possibly in part through a correlated telomerase activity in the hippocampus [192]. 
Telomerase is suggested to promote neurogenesis, however the detailed mechanism 
is still elusive. Telomerase may influence neurogenesis through extra-telomeric 
functions, and telomerase may thereby be implicated in depression through extra-
telomeric functions. Our previous finding showed that bipolar patients who 
responded well to lithium treatment had longer leukocyte telomere length. Whether 
this could reflect leukocyte telomerase activation are planned to be studied in newly 
diagnosed bipolar patients. We showed that lithium upregulated telomerase activity 
in the hippocampus of depressed rats.         
 Telomeres consist of DNA and protective protein complexes. A key protective 
complex is called shelterin and it includes TRF1, TRF2, TPP1, TIN1, POT1 and 
RAP1. Dysfunctional shelterin leads to insufficiant telomerase docking and increased 
DNA damage response which may result in cell cycle arrest [107]. Memebers of 
shelterin e.g. RAP1 was shown also to have extra-telomeric functions such as 
regulating gene expression [193]. The role of RAP1 is planned to be investigated in 
the FSL rat model. 
 The understanding of epigenetic regulation is increasing rapidly. Recently a number 
of studies showed that non-CpG methylation, primarily produced by DNMT3A, are 
abundunt and more dynamic than CpG methylation in adult brain [83]. DNMT3A is 
suggested to play a role in neurogenesis by modifying methylation in neuronal genes 
[194]. It would be interesting to investigate the function of DNMT3A in the 
depressed brain and the biological role of non-CpG methylation in depression. 
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                          “There are two ways to live: you can live as if nothing is a miracle;  
                                                                   you can live as if everything is a miracle.” 
                 “Logic will get you from A to B. Imagination will take you everywhere.” 
                                                                                                            ― Albert Einstein                                                                                                           
                                                                                    
                                             Brilliant imagination by Yu Chen. Beijing, China. 2015. 
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 We showed that the HDACi NaB can affect DNA methylation, however it is not 
clear how mechanistically epigenetic markers interact with each other, e.g. the order 
by which histone acetylation and/or DNA methylation predominantly influence one 
another. This emphasizes the importance of elucidating in detail how epigenetic 
drugs like NaB, and the structurally similar valproic acid, exert their mood stabilizing 
effects. 
 We found disturbed biogenesis in the Il6-targeting let-7 miRNA family in frontal 
cortex region of the FSL rats. In addition to LIN28B dysfunction, we also noticed a 
decreased DROSHA expression which implied a general reduction of miRNA 
biogenesis in frontal cortex region in depression states. In agreement, one study 
showed that most of the miRNAs were found to be decreased in the postmortem 
brain from drug-free depressive subjects [189]. In addition, a recent finding reported 
that enoxacin, an antibiotic drug that has miRNA production enhancement property, 
exhibited antidepressant-like effect in preclinical research (Smalheiser et al. 2014). 
MiRNAs show high stability in human paraffin-embedded tissues and plasma 
samples; a number of studies from cancer research have suggested the possibility that 
miRNA expression may be a useful tool to identify disease states and subtypes. It 
would be interesting to examine this idea also in depression. Thus, a comprehensive 
miRNA profiling is planned to be performed in the FSL frontal cortex. Furthermore, 
we found that physical activity reduced Il6 levels and selectively increased let-7i and 
miR-98 expression in the FSL frontal cortex, which was independent of Lin28b and 
Drosha changes but associated with upstream primary miRNA transcription changes, 
implying that other mechanisms (e.g. epigenetic) are involved in regulating let-7 
expression in response to physical activity. The reason to altered primary miRNA 
transcription is planned to be investigated in FSL frontal cortex. 
 
 
 
 
 
 
 
“By three methods we may learn wisdom:  
First, by reflection, which is noblest;  
Second, by imitation, which is easiest;  
and third by experience, which is the bitterest.” 
― Confucius   
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